We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Scientific (TMO) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) closed at $536.70 in the latest trading session, marking a -0.98% move from the prior day. This change lagged the S&P 500's daily loss of 0.7%. Meanwhile, the Dow lost 0.57%, and the Nasdaq, a tech-heavy index, lost 1.06%.
Heading into today, shares of the maker of scientific instrument and laboratory supplies had lost 2.48% over the past month, lagging the Medical sector's gain of 0.86% and the S&P 500's gain of 0.58% in that time.
Thermo Fisher Scientific will be looking to display strength as it nears its next earnings release. In that report, analysts expect Thermo Fisher Scientific to post earnings of $5.39 per share. This would mark year-over-year growth of 6.1%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.65 billion, down 0.29% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $22.37 per share and revenue of $43.54 billion, which would represent changes of -3.74% and -3.07%, respectively, from the prior year.
Any recent changes to analyst estimates for Thermo Fisher Scientific should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.03% lower within the past month. Thermo Fisher Scientific is currently a Zacks Rank #4 (Sell).
In terms of valuation, Thermo Fisher Scientific is currently trading at a Forward P/E ratio of 24.23. This valuation marks a discount compared to its industry's average Forward P/E of 29.82.
We can also see that TMO currently has a PEG ratio of 2.55. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.01 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 108, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow TMO in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher Scientific (TMO) Dips More Than Broader Markets: What You Should Know
Thermo Fisher Scientific (TMO - Free Report) closed at $536.70 in the latest trading session, marking a -0.98% move from the prior day. This change lagged the S&P 500's daily loss of 0.7%. Meanwhile, the Dow lost 0.57%, and the Nasdaq, a tech-heavy index, lost 1.06%.
Heading into today, shares of the maker of scientific instrument and laboratory supplies had lost 2.48% over the past month, lagging the Medical sector's gain of 0.86% and the S&P 500's gain of 0.58% in that time.
Thermo Fisher Scientific will be looking to display strength as it nears its next earnings release. In that report, analysts expect Thermo Fisher Scientific to post earnings of $5.39 per share. This would mark year-over-year growth of 6.1%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.65 billion, down 0.29% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $22.37 per share and revenue of $43.54 billion, which would represent changes of -3.74% and -3.07%, respectively, from the prior year.
Any recent changes to analyst estimates for Thermo Fisher Scientific should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.03% lower within the past month. Thermo Fisher Scientific is currently a Zacks Rank #4 (Sell).
In terms of valuation, Thermo Fisher Scientific is currently trading at a Forward P/E ratio of 24.23. This valuation marks a discount compared to its industry's average Forward P/E of 29.82.
We can also see that TMO currently has a PEG ratio of 2.55. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.01 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 108, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow TMO in the coming trading sessions, be sure to utilize Zacks.com.